Masaaki has demonstrated exceptional expertise in executing complex financial products and providing corporate solutions. His notable 8-year tenure at Goldman Sachs remarkably achieved a global top-three ranking in 2016. Transitioning from finance to biotechnology, he now leads TKG Therapeutics, Inc. as CEO. The company is at the forefront of drug discovery, specializing in the development of novel therapeutic drugs using nucleic acid medicine. The unique mechanism of action involves binding to target miRNA within the cancer cells, leading to the formation of long double-stranded DNA. This artificial DNA is identified by cGAS as a foreign substance, thereby activating the cGAS-STING pathway. This activation is crucial, as it results in the expression of type I interferon and the apoptosis of diseased cells, offering a promising new avenue in medical treatment.